Sepsis - Global Pipeline Review, H1 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 28, 2019--
The “Sepsis - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Sepsis - Pipeline Review, H1 2019 provides comprehensive information on the therapeutics under development for Sepsis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Sepsis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 9, 7, 1, 53, 6 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 23 and 2 molecules, respectively.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Sepsis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Sepsis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sepsis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sepsis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sepsis (Infectious Disease).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sepsis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sepsis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered
- Sepsis - Overview
- Therapeutics Development
- Therapeutics Assessment
- Companies Involved in Therapeutics Development
- Drug Profiles
- Dormant Projects
- Discontinued Products
- Product Development Milestones
- Adrenomed AG
- Am-Pharma BV
- Arch Biopartners Inc
- Asahi Kasei Pharma Corp
- Atox Bio Ltd
- Aurigene Discovery Technologies Ltd
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Co
- Cell2B Advanced Therapeutics SA
- Cells for Cells SA
- China Grand Pharmaceutical & Healthcare Holdings Ltd
- Chongqing Zhifei Biological Products Co Ltd
- Cilian AG
- Cynata Therapeutics Ltd
- CytaCoat AB
- Dr. Franz Kohler Chemie GmbH
- Endacea Inc
- Enlivex Therapeutics Ltd
- Enzychem Lifesciences Corp
- Evec Inc
- Immunwork Inc
- InflaRx NV
- Integrated BioTherapeutics Inc
- Lead Discovery Center GmbH
- MetrioPharm AG
- Microbiotix Inc
- Mochida Pharmaceutical Co Ltd
- Nosopharm SAS
- OncoImmune Inc
- Ono Pharmaceutical Co Ltd
- Opsona Therapeutics Ltd
- ProThera Biologics Inc
- Q BioMed Inc
- Ra Pharmaceuticals Inc
- Recce Ltd
- Regeneron Pharmaceuticals Inc
- Ribomic Inc
- Rimonyx Pharmaceuticals Ltd
- SciClone Pharmaceuticals Inc
- SetLance srl
- Shionogi & Co Ltd
- SK Biopharmaceuticals Co Ltd
- Syntiron LLC
- Takeda Pharmaceutical Co Ltd
- Therakind Ltd
- Therashock LLC
- Vascular BioSciences
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/9btouc
View source version on businesswire.com:https://www.businesswire.com/news/home/20190528005311/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Infectious Diseases Drugs
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/28/2019 06:10 AM/DISC: 05/28/2019 06:10 AM